Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Impact · against what's priced in

The positive EU CHMP opinion for ENFLONSIA is a regulatory win, but it is not a significant catalyst for MRK's valuation. The news provides a modest incremental revenue stream that does not address the primary valuation drivers of Keytruda's patent cliff or the mRNA cancer vaccine upside.

MRK+0.10: Not in the price yet
The price assumes

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

What matters in this story

How each ticker is affected

Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

What matters in this story

How each ticker is affected

Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

Track these names every morning.

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

Bristol Myers to merge scientific, clinical teams under new R&D structure

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment

Kaplan Fox Announces the Lead Plaintiff Deadline of November 30, 2026 in the Securities Class Action Against Anavex Life Sciences Corp. (AVXL)

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

What matters in this story

How each ticker is affected

Next reads from the same story arc

Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

What matters in this story

How each ticker is affected

Next reads from the same story arc

Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

Track these names every morning.

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

Bristol Myers to merge scientific, clinical teams under new R&D structure

The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment

Kaplan Fox Announces the Lead Plaintiff Deadline of November 30, 2026 in the Securities Class Action Against Anavex Life Sciences Corp. (AVXL)